A cell surface molecule, JL1; A specific target for diagnosis and treatment of leukemias

Leukemia

Volumn 12, Issue 10, 1998, Pages 1583-1590

  Park, W S ^a   Bae, Y M ^a,b   Chung, D H ^a   Kim, T J ^a   Choi, E Y ^a   Chung, J K ^a   Lee, M C ^a   Park, S Y ^a   Park, M H ^a   Park, S H ^a  

^a Seoul National University   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunodiagnosis; Immunotherapy; JL1 antigen; Pan leukemic marker; T cell differentiation antigen

Indexed keywords

DIFFERENTIATION ANTIGEN; JL1 ANTIGEN; MEMBRANE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 17344366564     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401161     Document Type: Article

References (11)

1. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997; 9: 717-722.
2. Oshimi K, Seto T, Oshimi Y, Masuda M, Okumura K, Mizoguchi H. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody. Blood 1991; 77: 1044-1049.
3. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 12: 1974-1981.
4. Mach JP, Pelegrin A, Foilli S, Buchegger F. Radiolabeled monoclonal antibodies as anti-tumor missiles, their diagnostic success and therapeutic potential. Bull Acad Natl Med 1992; 176: 879-889.
5. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med 1996; 2: 979-984.
6. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4.
7. Real FX, Mattes MJ, Houghton AN, Oettgen HF, Lloyd KO, Old LJ. Class I (unique) tumor antigens of human melanoma. Identification of 90000 dalton cell surface glycoprotein by autologous antibody. J Exp Med 1984; 160: 1219-1233.
8. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 35-42.
9. Brichard V, Van Pel A, Woelfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HAL-A2 melanomas. J Exp Med 1993; 178: 489-495.
10. Cattoretti G, Berti E, Parravicini C, Buscaglia M, Cappio F, Caputo R, Cerri A, Crosti L, Delia D, Gaiera G, Polli N. Expression of CD1 molecules on dendritic cells: ontogeny, epitope analysis on normal and malignant cells, and tissue distribution. In: Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, Kr von dem Borne AEG (eds). Leukocyte Typing IV. White Cell Differentiation Antigens. Oxford University Press: London, 1989, pp 262-264.
11. Park SH, Mahoney RJ, Given SR, Fajardo MA, Dubey DP, Yunis EJ. Serological identification of thymocyte differentiation antigens. Hum Immunol 1988; 22: 151-162.